Standard BioTools Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Standard BioTools Inc. (LAB) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$18.03 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-02-25.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2021-02-25
- Standard BioTools Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2020-12-31 was -$18.03M.
- Standard BioTools Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2020-09-30 was -$6.00M.
- Standard BioTools Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2020-06-30 was -$13.02M.
- Standard BioTools Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2020-03-31 was -$15.98M.
- Standard BioTools Inc. net income (loss) available to common stockholders, diluted for fiscal 2013 was -$16.53M.
- Standard BioTools Inc. net income (loss) available to common stockholders, diluted for fiscal 2012 was -$19.02M.
- Standard BioTools Inc. net income (loss) available to common stockholders, diluted for fiscal 2011 was -$32.37M.
- Standard BioTools Inc. net income (loss) available to common stockholders, diluted for fiscal 2010 was -$16.90M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$18.03M 10-K · filed 2021-02-25 | -$24.02M derived: sum of 2 quarters · filed 2021-02-25 | -$37.04M derived: sum of 3 quarters · filed 2021-02-25 | -$53.02M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-09-30 | -$6.00M 10-K · filed 2021-02-25 | -$19.01M derived: sum of 2 quarters · filed 2021-02-25 | -$34.99M derived: sum of 3 quarters · filed 2021-02-25 | -$47.68M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-06-30 | -$13.02M 10-K · filed 2021-02-25 | -$29.00M derived: sum of 2 quarters · filed 2021-02-25 | -$41.68M derived: sum of 3 quarters · filed 2021-02-25 | -$54.57M derived: sum of 4 quarters · filed 2021-02-25 |
| 2020-03-31 | -$15.98M 10-K · filed 2021-02-25 | -$28.66M derived: sum of 2 quarters · filed 2021-02-25 | -$41.55M derived: sum of 3 quarters · filed 2021-02-25 | -$55.30M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-12-31 | -$12.69M 10-K · filed 2021-02-25 | -$25.57M derived: sum of 2 quarters · filed 2021-02-25 | -$39.33M derived: sum of 3 quarters · filed 2021-02-25 | -$64.79M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-09-30 | -$12.89M 10-K · filed 2021-02-25 | -$26.64M derived: sum of 2 quarters · filed 2021-02-25 | -$52.10M derived: sum of 3 quarters · filed 2021-02-25 | -$66.88M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$13.75M 10-K · filed 2021-02-25 | -$39.22M derived: sum of 2 quarters · filed 2021-02-25 | -$53.99M derived: sum of 3 quarters · filed 2021-02-25 | -$68.74M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$25.46M 10-K · filed 2021-02-25 | -$40.24M derived: sum of 2 quarters · filed 2021-02-25 | -$54.99M derived: sum of 3 quarters · filed 2021-02-25 | -$71.23M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$14.78M 10-K · filed 2020-02-27 | -$29.52M derived: sum of 2 quarters · filed 2020-02-27 | -$45.77M derived: sum of 3 quarters · filed 2020-02-27 | -$59.01M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-09-30 | -$14.75M 10-K · filed 2020-02-27 | -$30.99M derived: sum of 2 quarters · filed 2020-02-27 | -$44.24M derived: sum of 3 quarters · filed 2020-02-27 | -$54.69M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$16.24M 10-K · filed 2020-02-27 | -$29.49M derived: sum of 2 quarters · filed 2020-02-27 | -$39.94M derived: sum of 3 quarters · filed 2020-02-27 | -$55.89M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$13.25M 10-K · filed 2020-02-27 | -$23.70M derived: sum of 2 quarters · filed 2020-02-27 | -$39.65M derived: sum of 3 quarters · filed 2020-02-27 | -$56.58M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$10.46M 10-K · filed 2019-03-18 | -$26.40M derived: sum of 2 quarters · filed 2019-03-18 | -$43.33M derived: sum of 3 quarters · filed 2019-03-18 | -$60.53M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-09-30 | -$15.94M 10-K · filed 2019-03-18 | -$32.88M derived: sum of 2 quarters · filed 2019-03-18 | -$50.08M derived: sum of 3 quarters · filed 2019-03-18 | -$67.78M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-06-30 | -$16.93M 10-K · filed 2019-03-18 | -$34.13M derived: sum of 2 quarters · filed 2019-03-18 | -$51.83M derived: sum of 3 quarters · filed 2019-03-18 | -$71.62M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-03-31 | -$17.20M 10-K · filed 2019-03-18 | -$34.90M derived: sum of 2 quarters · filed 2019-03-18 | -$54.69M derived: sum of 3 quarters · filed 2019-03-18 | -$73.30M derived: sum of 4 quarters · filed 2019-03-18 |
| 2016-12-31 | -$17.70M 10-K · filed 2018-03-08 | -$37.48M derived: sum of 2 quarters · filed 2018-03-08 | -$56.10M derived: sum of 3 quarters · filed 2018-03-08 | -$75.98M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-09-30 | -$19.79M 10-K · filed 2018-03-08 | -$38.40M derived: sum of 2 quarters · filed 2018-03-08 | -$58.29M derived: sum of 3 quarters · filed 2018-03-08 | -$71.17M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | -$18.62M 10-K · filed 2018-03-08 | -$38.50M derived: sum of 2 quarters · filed 2018-03-08 | -$51.38M derived: sum of 3 quarters · filed 2018-03-08 | -$60.65M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | -$19.88M 10-K · filed 2018-03-08 | -$32.76M derived: sum of 2 quarters · filed 2018-03-08 | -$42.03M derived: sum of 3 quarters · filed 2018-03-08 | -$57.27M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | -$12.88M 10-K · filed 2017-03-03 | -$22.15M derived: sum of 2 quarters · filed 2017-03-03 | -$37.38M derived: sum of 3 quarters · filed 2017-03-03 | -$53.31M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-09-30 | -$9.27M 10-K · filed 2017-03-03 | -$24.50M derived: sum of 2 quarters · filed 2017-03-03 | -$40.44M derived: sum of 3 quarters · filed 2017-03-03 | -$51.38M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-06-30 | -$15.24M 10-K · filed 2017-03-03 | -$31.17M derived: sum of 2 quarters · filed 2017-03-03 | -$42.11M derived: sum of 3 quarters · filed 2017-03-03 | -$55.90M derived: sum of 4 quarters · filed 2017-03-03 |
| 2015-03-31 | -$15.93M 10-K · filed 2017-03-03 | -$26.88M derived: sum of 2 quarters · filed 2017-03-03 | -$40.66M derived: sum of 3 quarters · filed 2017-03-03 | -$53.35M derived: sum of 4 quarters · filed 2017-03-03 |
| 2014-12-31 | -$10.94M 10-K · filed 2016-02-29 | -$24.73M derived: sum of 2 quarters · filed 2016-02-29 | -$37.42M derived: sum of 3 quarters · filed 2016-02-29 | -$52.83M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-09-30 | -$13.79M 10-K · filed 2016-02-29 | -$26.47M derived: sum of 2 quarters · filed 2016-02-29 | -$41.89M derived: sum of 3 quarters · filed 2016-02-29 | -$46.53M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | -$12.68M 10-K · filed 2016-02-29 | -$28.10M derived: sum of 2 quarters · filed 2016-02-29 | -$32.74M derived: sum of 3 quarters · filed 2016-02-29 | -$37.02M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | -$15.41M 10-K · filed 2016-02-29 | -$20.06M derived: sum of 2 quarters · filed 2016-02-29 | -$24.34M derived: sum of 3 quarters · filed 2016-02-29 | -$28.39M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$4.64M 10-K · filed 2015-02-26 | -$8.93M derived: sum of 2 quarters · filed 2015-02-26 | -$12.97M derived: sum of 3 quarters · filed 2015-02-26 | -$16.53M 10-K · filed 2014-03-12 |
| 2013-09-30 | -$4.29M 10-K · filed 2015-02-26 | -$8.33M derived: sum of 2 quarters · filed 2015-02-26 | -$11.88M derived: sum of 3 quarters · filed 2015-02-26 | -$15.48M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | -$4.05M 10-K · filed 2015-02-26 | -$7.60M derived: sum of 2 quarters · filed 2015-02-26 | -$11.20M derived: sum of 3 quarters · filed 2015-02-26 | -$15.35M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | -$3.55M 10-K · filed 2015-02-26 | -$7.15M derived: sum of 2 quarters · filed 2015-02-26 | -$11.30M derived: sum of 3 quarters · filed 2015-02-26 | -$15.88M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | -$3.60M 10-K · filed 2014-03-12 | -$7.75M derived: sum of 2 quarters · filed 2014-03-12 | -$12.33M derived: sum of 3 quarters · filed 2014-03-12 | -$19.02M 10-K · filed 2014-03-12 |
| 2012-09-30 | -$4.15M 10-K · filed 2014-03-12 | -$8.73M derived: sum of 2 quarters · filed 2014-03-12 | -$15.42M 10-Q · filed 2012-11-09 | -$18.88M derived: sum of 4 quarters · filed 2014-03-12 |
| 2012-06-30 | -$4.58M 10-K · filed 2014-03-12 | -$11.27M 10-Q · filed 2012-08-14 | -$14.73M derived: sum of 3 quarters · filed 2014-03-12 | -$19.22M derived: sum of 4 quarters · filed 2014-03-12 |
| 2012-03-31 | -$6.69M 10-K · filed 2014-03-12 | -$10.15M derived: sum of 2 quarters · filed 2014-03-12 | -$14.64M derived: sum of 3 quarters · filed 2014-03-12 | -$21.82M derived: sum of 4 quarters · filed 2014-03-12 |
| 2011-12-31 | -$3.46M 10-K · filed 2013-03-12 | -$7.95M derived: sum of 2 quarters · filed 2013-03-12 | -$15.13M derived: sum of 3 quarters · filed 2013-03-12 | -$32.37M 10-K · filed 2014-03-12 |
| 2011-09-30 | -$4.49M 10-K · filed 2013-03-12 | -$11.68M derived: sum of 2 quarters · filed 2013-03-12 | -$28.91M 10-Q · filed 2012-11-09 | -$31.99M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-06-30 | -$7.19M 10-K · filed 2013-03-12 | -$24.42M 10-Q · filed 2012-08-14 | -$27.50M derived: sum of 3 quarters · filed 2013-03-12 | -$30.88M derived: sum of 4 quarters · filed 2013-03-12 |
| 2011-03-31 | -$17.24M 10-K · filed 2013-03-12 | -$20.32M derived: sum of 2 quarters · filed 2013-03-12 | -$23.70M derived: sum of 3 quarters · filed 2013-03-12 | -$28.52M derived: sum of 4 quarters · filed 2013-03-12 |
| 2010-12-31 | -$3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | -$6.46M derived: sum of 2 quarters · filed 2013-03-12 | -$11.28M derived: sum of 3 quarters · filed 2013-03-12 | -$16.90M 10-K · filed 2013-03-12 |
| 2010-09-30 | -$3.38M 10-Q · filed 2011-11-14 | -$8.20M derived: sum of 2 quarters · filed 2011-11-14 | -$13.82M 10-Q · filed 2011-11-14 | |
| 2010-06-30 | -$4.82M 10-Q · filed 2011-08-09 | -$10.44M 10-Q · filed 2011-08-09 | ||
| 2009-12-31 | -$19.13M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |